Management of Thrombocytopenia

Initial Assessment and Risk Stratification

The American College of Cardiology suggests that mild thrombocytopenia (≥50 × 10⁹/L) generally does not require immediate intervention in the absence of bleeding symptoms 1
For patients with moderate thrombocytopenia (25-50 × 10⁹/L), dose-modified anticoagulation strategies are required if anticoagulation is indicated, as recommended by the Journal of Thrombosis and Haemostasis 2, 3
Severe thrombocytopenia (<25 × 10⁹/L) requires temporary discontinuation of anticoagulation unless high thrombotic risk with platelet transfusion support, according to the Journal of Thrombosis and Haemostasis 2, 3
A reverse A/G ratio (albumin < globulin) suggests chronic liver disease, malignancy, or chronic inflammatory states that may explain thrombocytopenia, as indicated by the Journal of the American College of Cardiology 4

For platelets ≥50 × 10⁹/L, full therapeutic anticoagulation without platelet transfusion support should be administered, as recommended by the Journal of Thrombosis and Haemostasis 2
Low molecular weight heparin (LMWH) is the preferred anticoagulant in cancer-associated thrombosis, according to the Journal of Thrombosis and Haemostasis 2
Direct oral anticoagulants (DOACs) should be avoided in patients with severe thrombocytopenia (<50 × 10⁹/L) and certain cancer types due to increased bleeding risk, as indicated by the Journal of Thrombosis and Haemostasis 2

For acute CAT with high-risk features, therapeutic doses of anticoagulation with platelet transfusion support to maintain platelet counts at 40-50 × 10⁹/L should be used, as recommended by the Journal of Thrombosis and Haemostasis 2, 3
Aspirin improves 7-day survival without increasing bleeding risk in cancer patients with thrombocytopenia and ACS, according to the Journal of the American College of Cardiology 4
Dual antiplatelet therapy (aspirin plus clopidogrel) can be used for platelet counts >30,000/μL, as indicated by the Journal of the American College of Cardiology 4

Platelet count should be monitored daily until stable or improving, as recommended by Praxis Medical Insights 3
When platelet count recovers to >50 × 10⁹/L, reassess need for continued anticoagulation, according to Praxis Medical Insights 3

DOACs should not be used in patients with severe thrombocytopenia (<50 × 10⁹/L) as safety data are lacking, as indicated by the Journal of Thrombosis and Haemostasis 2
If heparin-induced thrombocytopenia (HIT) is suspected, discontinue all heparin products and consider non-heparin anticoagulants, as recommended by Praxis Medical Insights 3

Immediate emergency department referral is indicated if patient is acutely unwell, active significant bleeding is present, or rapid decline in platelet count is observed, as recommended by Praxis Medical Insights 1
Hematology referral is indicated if cause of thrombocytopenia is unclear, platelet count continues to decline despite management, or platelet count drops below 50,000/μL, according to Praxis Medical Insights 1